November 30, 2024 - 15:12

MARIETTA — Memorial Health System has announced the addition of Dr. Albeir Mousa, a highly qualified vascular surgeon, to its team at Marietta Memorial Hospital. Dr. Mousa brings a wealth of experience and expertise, enhancing the capabilities of the vascular team at MHS. His arrival is expected to significantly improve the level of care available to patients in the region.
Dr. Mousa is known for his proficiency in innovative vascular technologies and research, which will be instrumental in optimizing patient outcomes. His commitment to providing the highest quality of care aligns with the mission of Memorial Health System to deliver exceptional healthcare services to the community.
As he begins seeing patients, Dr. Mousa is poised to make a positive impact on the local healthcare landscape, ensuring that individuals in need of vascular care have access to the latest advancements and treatments available. The integration of his skills into the MHS team marks a promising development for patient care in the area.
July 30, 2026 - 02:45
Texas health issues alert after 4 Montgomery County residents infected with measlesTexas health authorities have issued a public health alert after four members of an unvaccinated family in Montgomery County tested positive for measles. The cases, all linked to a single household...
July 29, 2026 - 08:53
Local nonprofits call for changes at Bexar County jail over custody deaths, healthcare concernsHouston, Dallas, and San Antonio operate the three largest county jail systems in Texas. But so far this year, Bexar County has recorded the highest number of deaths among inmates in custody,...
July 28, 2026 - 17:12
Private Equity Firm Unloads Mental Health Chain Into Muni MarketA private equity firm based in Connecticut is moving to offload a network of mental health clinics and sober-living facilities, using a financing structure that taps into the municipal bond market....
July 28, 2026 - 03:52
Peptides are the latest wellness trend – but do they work?A US drug advisory committee has recently given a nod of approval to several experimental peptides, signaling a potential shift in how these compounds are viewed by regulators. Yet despite the...